Combined early treatment with chelating agents DMSA and CaDTPA in acute oral cadmium exposure.
The influence of chelating agents: meso-2,3-dimercaptosuccinic acid (DMSA); calcium trisodium diethylenetriaminepentaacetate (CaDTPA) and their combination on mobilisation of cadmium (Cd) was compared in female albino rats. After oral Cd administration chelators were applied either orally (DMSA) or intraperitoneally (CaDTPA) at various short time intervals after Cd. Three experiments were carried out with four treatment groups in each: 1) Cd (control); 2) Cd+DMSA; 3) Cd+CaDTPA; 4) Cd+DMSA+CaDTPA. Time intervals for chelator treatment after Cd administration were: immediate application in the first, half an hour in the second and one hour in the third experiment. At the end of each experiment cadmium was analysed in kidney and liver. Additionally in experiment 3 essential elements (Fe, Cu, Zn) were also determined in the same organs. In experiment 2 the effect of the treatment on urinary elimination of cadmium, copper and zinc were analysed. Results showed that the efficiency of Cd removal from the body (kidneys and liver) is lower when the time between Cd and chelating agents administration is longer. The two chelators differ in efficiency in mobilizing Cd, with DMSA being more efficient than CaDTPA. The combined therapy with the two chelators gave generally better results. It seems that DMSA which is given orally after oral Cd administration removes this element very efficiently from the gastrointestinal tract. CaDTPA, however, which is given parenterally removes absorbed Cd less efficiently, Organs are not significantly depleted in iron and copper after chelation treatment. Only zinc concentration was, however, significantly lower in the liver and higher in kidneys only after CaDTPA and combined DMSA+CaDTPA chelation.
Sarić
Marijana Matek
MM
Mineral Metabolism Unit, Institute for Medical Research and Occupational Health, Zagreb, Croatia.
Blanusa
Maja
M
Juresa
Dijana
D
Sarić
Marija
M
Varnai
Veda Marija
VM
Kostial
Krista
K
D000284:Administration, Oral; D000818:Animals; D002104:Cadmium / Q000032:analysis / Q000633:toxicity*; D002614:Chelating Agents / Q000627:therapeutic use*; D003300:Copper / Q000032:analysis; D004359:Drug Therapy, Combination; D005260:Female; D005998:Glycine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D007274:Injections, Intraperitoneal; D007668:Kidney / Q000737:chemistry; D008099:Liver / Q000737:chemistry; D009942:Organometallic Compounds / Q000627:therapeutic use*; D004369:Pentetic Acid; D051381:Rats; D017208:Rats, Wistar; D004113:Succimer / Q000627:therapeutic use*; D015032:Zinc / Q000032:analysis
D002614:Chelating Agents; D009942:Organometallic Compounds; D002104:Cadmium; D003300:Copper; D004369:Pentetic Acid; D004113:Succimer; D015032:Zinc; D005998:Glycine